TheraRadar
Data updated: May 26, 2026

ARESTIN (minocycline hydrochloride)

Infectious Disease Approved 2001-02-16

ARESTIN (minocycline hydrochloride) is indicated as an adjunct to scaling and root planing (SRP) procedures for the reduction of pocket depth in patients with adult periodontitis. It may be utilized as part of a comprehensive periodontal maintenance program that includes professional cleanings and diligent oral hygiene.

Source: FDA Label • ORAPHARMA

How ARESTIN Works

The specific mechanism by which ARESTIN reduces pocket depth when used as an adjunct to scaling and root planing is unknown. Minocycline, the active ingredient, is a member of the tetracycline class of antibiotics and exerts its bacteriostatic effect by inhibiting protein synthesis.

1
Indication
--
Phase 3 Trials
25
Years on Market

Details

Status
Prescription
First Approved
2001-02-16
Routes
DENTAL
Dosage Forms
POWDER, EXTENDED RELEASE

Companies

Active Ingredient: MINOCYCLINE HYDROCHLORIDE

ARESTIN Approval History

2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
12 FDA actions from 2001 to 2024
May 2024 SUPPL
Label · Labeling
May 2017 SUPPL
Label · Labeling
Jul 2012 SUPPL
Label · Labeling

What ARESTIN Treats

1 indications

ARESTIN is approved for 1 conditions since its original approval in 2001. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Periodontitis
Source: FDA Label
📋

Clinical Trial Registry

5 trials
Trial Sponsor ID Phase Status Title
NCT06246396 IRB202301939 2R01HL132448-05A1 Ph 4 recruiting Antihypertensive Mechanisms of Minocycline in Resistant Hypertension
NCT05826912 APT-TBI-01 APT-TBI-01 Ph 2 enrolling by invitation Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury
NCT02203552 results posted OSU-13165 NCI-2014-00851 Ph 2 completed Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer
NCT02297412 results posted RU221408I NCI-2016-01592, RU221408I Ph 2 completed Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel
NCT04076098 RP139-02/18 Ph 4 completed Locally Delivered Minocycline in Advanced Periodontitis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ARESTIN FDA Label Details

Indications & Usage

FDA Label (PDF)

ARESTIN is indicated for the treatment of Periodontitis.

Track ARESTIN with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.